Evidence overview
NMN
NMN (nicotinamide mononucleotide) is a NAD+ precursor that has attracted significant consumer and research attention as an anti-aging compound. The human clinical research base is still small and recent - much smaller than the preclinical animal and cell literature that drove early enthusiasm - and the field is actively working out whether raising NAD+ blood levels translates to specific clinical outcomes in adults.
Most studied for
Coverage pending
PubMed coverage
Coverage pending
Safety profile
In your full report
Mechanism class
Direct precursor to NAD+ (nicotinamide adenine dinucleotide), a coenzyme central to cellular energy metabolism...
Study coverage
Study coverage by goal
PubMed counts for NMN grouped by the goal each study targets.
Evidence overview is temporarily unavailable for NMN.
Evidence
What the evidence covers
The terrain of the published literature, not its conclusions.
NMN (nicotinamide mononucleotide) is a direct precursor to NAD+, a coenzyme central to cellular energy metabolism and sirtuin-pathway signaling. The supplement was popularized by anti-aging research demonstrating NAD+ decline with age across many tissues. The human clinical literature is small and recent: most published studies are short trials (4-12 weeks) in healthy or modestly metabolically-impaired adults, examining NAD+ blood levels, glucose and lipid metabolism, exercise-related outcomes, and various wellness markers. The preclinical (animal and cell) literature is substantially larger and is what drove early consumer marketing.
The outcome dimensions covered most heavily in the human literature are NAD+ blood levels (the most-studied biochemical measurement in the field), glucose and lipid metabolism in adults at risk for metabolic dysfunction, exercise performance and muscle function in middle-aged and older adults, and general wellness markers. The central research question across this literature is whether changes in NAD+ biomarkers translate to specific clinical outcomes that consumers care about, a question recent comprehensive meta-analyses have examined across the still-young trial base.
Demographically, the human trials concentrate on healthy middle-aged and older adults (the marketing-target demographic). Form variation (NMN HCl, liposomal NMN, sublingual formulations) is an active practical question, with manufacturers claiming differential bioavailability and route-of-administration advantages, though head-to-head trial data is thin. The single largest gap in the NMN literature is duration: most published human trials are 4-12 weeks, which is short relative to the timescale on which age-related decline operates. Long-term safety and durability of effects remain open questions.
Safety
Safety summary
Common adverse events, drug interactions, and special populations.
NMN is generally well-tolerated in the published human trials, which have used doses ranging from 250 mg/day to 1,200 mg/day for up to 12 weeks. The most-common adverse effects are mild gastrointestinal discomfort and headache. No tolerable upper limit has been established. Long-term safety data are limited because the published human trial literature is recent and short-duration. Drug interactions are not well-characterized; theoretical concerns about interactions with cancer treatments (because NAD+ supplementation may interact with cell-proliferation pathways relevant to oncology) have been raised but are not consistently documented in clinical research. The FDA's regulatory positioning on NMN as a dietary supplement has shifted in recent years and remains a meaningful caveat. People with active cancer, those on chemotherapy, or those with significant pre-existing health conditions should consult a clinician before starting.
This summary is informational and not medical advice. Consult a clinician before starting or changing any supplement, especially if you take prescription medications.
Foundations
Foundation of the evidence base
A few studies the field anchors on. Not the full picture, just the starting points.
Recent comprehensive systematic review of NAD+ supplementation in anti-aging contexts, covering both preclinical and clinical evidence. While the scope spans multiple NAD+ precursors (NMN, nicotinamide riboside, niacin, niacinamide), it provides the most-current supplement-level reference for where the NMN-related evidence stands.
View on PubMedMost-recent meta-analysis specifically on oral NMN for glucose and lipid metabolism in adults. Represents the largest body of NMN-specific human clinical evidence to date and is the field reference document on whether NAD+ biomarker changes translate to metabolic outcomes.
View on PubMed
Limitations
What this page doesn't answer
Where the public summary stops and the personalized report begins.
This page summarizes the NMN literature at a general level. It does not address whether NMN is the right NAD+ precursor for your goal (alternatives include nicotinamide riboside (NR) and niacin/niacinamide, each with different evidence bases), what dose to use, how long to take it (most trials are 4-12 weeks, with limited long-term human data), how NMN fits with your specific health context, or whether you have any conditions that warrant clinician consultation first. The emerging nature of the NMN literature means many of the most-asked consumer questions cannot yet be answered with confidence by either this page or the personalized report.
Personalized to you
Get a personalized NMN report
Your free first report adds the things this page doesn't: per-goal evidence breakdown, demographic-specific findings, full citation list, and a safety section tailored to your profile.
Free first report. No credit card. Cancel anytime.
Get notified when new evidence appears
We'll email you when the literature on NMN materially updates. No account required.